Edge­wise shares spike on Phase 2 suc­cess for mus­cu­lar dy­s­tro­phy drug

Edge­wise Ther­a­peu­tics’ treat­ment can­di­date for sev­er­al forms of mus­cu­lar dy­s­tro­phy has hit the pri­ma­ry end­point in a mid-stage study, set­ting in mo­tion plans for reg­u­la­to­ry …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER